Published in Medical Letter on the CDC and FDA, July 8th, 2007
Astellas' European subsidiary submitted a Marketing Authorization Application (MAA) for Advagraf under the centralized procedure to the European Medicines Agency (EMEA) in January 2006. This was followed by the European Commission's approval of Advagraf on April 23, 2007. Advagraf is indicated for the "Prophylaxis of transplant rejection in adult kidney or liver allograft...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA